IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC

被引：2
|
作者：
Wang, Jie
Fan, Yun
Fang, Jian
He, Jianxing
Liu, Yunpeng
Tao, Min
Altorki, Nasser
Felip, Enriqueta
Wakelee, Heather
Vallieres, Eric
Belleli, Rossella
McNally, Virginia
Bennett, Elizabeth
Gitlitz, Barbara J.
Zhou, Caicun
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT239
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT239
引用
收藏
页数：2
相关论文
共 50 条
  • [21] IMpower010 5-y Subgroup Analysis and Relapse Patterns: Phase 3 Study of Atezolizumab vs BSC in Stage II-IIIA NSCLC
    Felip, E.
    Wakelee, H. A.
    Vallieres, E.
    Martinez-Marti, A.
    Goloborodko, O.
    Zhou, C.
    Rittmeyer, A.
    Chella, A.
    Reck, M.
    Csoszi, T.
    Bondarenko, I.
    Kenmotsu, H.
    Schutte, W.
    Ding, B.
    Zhu, Q.
    Ballinger, M.
    Bennett, E.
    Gitlitz, B. J.
    Altorki, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S8 - S9
  • [22] Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial (vol 398, pg 1344, 2021)
    Felip, Enriqueta
    Altorki, Nasser
    Zhou, Caicun
    Csoszi, Tibor
    Vynnychenko, Ihor
    Goloborodko, Oleksandr
    Luft, Alexander
    Akopov, Andrey
    Martinez-Marti, Alex
    Kenmotsu, Hirotsugu
    Chen, Yuh-Min
    Chella, Antonio
    Sugawara, Shunichi
    Voong, David
    Wu, Fan
    Yi, Jing
    Deng, Yu
    McCleland, Mark
    Bennett, Elizabeth
    Gitlitz, Barbara
    Wakelee, Heather
    LANCET, 2021, 398 (10312): : 1686 - 1686
  • [23] IMpower010: ctDNA status and 5y DFS follow up in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)
    Wakelee, H.
    Reck, M.
    Felip, E.
    Altorki, N. K.
    Vallieres, E.
    Liersch, R.
    Oizumi, S.
    Tanaka, H.
    Hamm, J. T.
    McCune, S.
    Bennett, E.
    Gitlitz, B. J.
    McNally, V. A.
    Novello, S.
    Ballinger, M.
    Zou, W.
    Nabet, B.
    Srivastava, M.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S779 - S780
  • [24] Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non-small cell lung cancer in the randomized phase III IMpower010 trial
    Lee, Jay M.
    Vallieres, Eric
    Ding, Beiying
    Johnson, Ann
    Bhagwakar, Jan
    Rashidi, Sanam
    Zhu, Qian
    Gitlitz, Barbara J.
    Weksler, Benny
    Costas, Kimberly
    Altorki, Nasser
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2023, 166 (03):
  • [25] IMpower010: Characterisation of patients (pts) with stage II-IIIA PD-L1 TC≥50% NSCLC who were disease-free at 5 years (5yDF) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after resection and adjuvant (adj) chemotherapy (chemo)
    Felip, E.
    Vallieres, E.
    Gologordko, O.
    Martinez-Marti, A.
    Zhou, C.
    Altorki, N. K.
    Rittmeyer, A.
    Chella, A.
    Reck, M.
    Schuette, W.
    Okada, M.
    Liersch, R.
    Teixeira, M. E.
    Bennett, E.
    Gitlitz, B. J.
    Srivastava, M.
    Ballinger, M.
    Zhu, C.
    Crama, L.
    Wakelee, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S780 - S781
  • [26] IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)
    Altorki, N. K.
    Reck, M.
    Wakelee, H.
    Felip, E.
    Vallieres, E.
    Liersch, R.
    Oizumi, S.
    Tanaka, H.
    Novello, S.
    McCune, S.
    Li, H.
    Molinero, L.
    Mueller, S.
    Bennett, E.
    Gitlitz, B. J.
    McNally, V. A.
    Ballinger, M.
    Nabet, B.
    Srivastava, M. K.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S732 - S733
  • [27] Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
    Herbst, Roy S.
    Wu, Yi-Long
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Wang, Jie
    Kato, Terufumi
    Goldman, Jonathan W.
    Laktionov, Konstantin
    Kim, Sang-We
    Yu, Chong-Jen
    Vu, Huu Vinh
    Lu, Shun
    Lee, Kye Young
    Mukhametshina, Guzel
    Akewanlop, Charuwan
    de Marinis, Filippo
    Bonanno, Laura
    Domine, Manuel
    Shepherd, Frances A.
    Urban, Damien
    Huang, Xiangning
    Bolanos, Ana
    Stachowiak, Marta
    Tsuboi, Masahiro
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (10) : 1830 - +
  • [28] Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).
    Herbst, Roy S.
    Tsuboi, Masahiro
    John, Tom
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    De Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu
    Dechaphunkul, Arunee
    Kowalski, Dariusz M.
    Poole, Lynne
    Stachowiak, Marta
    Rukazenkov, Yuri
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [29] Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).
    Herbst, Roy S.
    Tsuboi, Masahiro
    John, Tom
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    de Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu
    Dechaphunkul, Arunee
    Kowalski, Dariusz M.
    Poole, Lynne
    Stachowiak, Marta
    Rukazenkov, Yuri
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL)
  • [30] Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
    Tsuboi, M.
    Wu, Y-L.
    Grohe, C.
    John, T.
    Majem Tarruella, M.
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S-W.
    Yu, C-J.
    Vu, H. Vinh
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A. L.
    Huang, X.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1413 - S1414
12345